发明名称 BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
摘要 The present invention provides compounds of Formula I,;;pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
申请公布号 US2016185815(A1) 申请公布日期 2016.06.30
申请号 US201514951989 申请日期 2015.11.25
申请人 Enanta Pharmaceuticals, Inc. 发明人 Wang Guoqiang;Or Yat Sun;Shen Ruichao;Long Jiang;Dai Peng;Xing Xuechao;He Jing
分类号 C07J41/00;C07J43/00 主分类号 C07J41/00
代理机构 代理人
主权项 1. A compound represented by Formula I or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, or combination thereof: wherein: Ra is hydrogen or substituted or unsubstituted —C1-C8 alkyl; preferably Ra is hydrogen or methyl; Rb is selected from from the group consisting of: 1) Hydrogen;2) —C(O)NR10R11;3) —C(O)NHSO2R1; and4) —SO2R1; R1 is selected from the group consisting of: 1) Halogen;2) Hydroxyl;3) Substituted or unsubstituted —C1-C8 alkyl;4) Substituted or unsubstituted —C2-C8 alkenyl;5) Substituted or unsubstituted —C2-C8 alkynyl;6) Substituted or unsubstituted —C3-C8 cycloalkyl;7) Substituted or unsubstituted aryl;8) Substituted or unsubstituted arylalkyl;9) Substituted or unsubstituted heterocycloalkyl;10) Substituted or unsubstituted heteroaryl;11) Substituted or unsubstituted heteroarylalkyl; and12) —NR10R11; R2 is selected from the group consisting of: 1) Hydrogen;2) Substituted or unsubstituted —C1-C8 alkyl;3) Substituted or unsubstituted —C2-C8 alkenyl;4) Substituted or unsubstituted —C2-C8 alkynyl;5) Substituted or unsubstituted arylalkyl; and6) Substituted or unsubstituted aryl. preferably R2 is hydrogen; m is selected from 0, 1, 2 and 3, preferably m is from 0 to 2; R3 is hydrogen, hydroxyl, —OSO3H, —OSO3−, —OAc, —OPO3H2 or —OPO32−; preferably R3 is hydrogen; R4 is hydrogen, halogen, CN, N3, hydroxyl, —OSO3H, —OSO3−, —OAc, —OPO3H2, —OPO32−, —SR2 or —NHR2, wherein, R2 is as defined previously; preferably R4 is hydrogen; Or R3 and R4 are taken together with the carbons they attached form —CH═CH— or cycloalkyl ring or heterocycloalkyl ring such as, but not limited to cyclopropyl, or epoxide; R5 and R6 are independently selected from hydrogen or hydroxyl protecting group such as, but not limited to acetyl, trimethyl silyl, or benzyl; preferably R5 and R6 are hydrogen; R7 is selected from the group consisting of: 1) Hydrogen;2) Halogen;3) Substituted or unsubstituted —C1-C8 alkyl;4) Substituted or unsubstituted —C2-C8 alkenyl;5) Substituted or unsubstituted —C2-C8 alkynyl; and6) Substituted or unsubstituted —C3-C8 cycloalkyl; preferably R7 is C1-C4-alkyl, more preferably R7 is ethyl; R10 and R11 are each independently selected from hydrogen,substituted or unsubstituted —C1-C8 alkyl, substituted or unsubstituted —C2-C8 alkenyl, Substituted or unsubstituted —C2-C8 alkynyl, substituted or unsubstituted —C3-C8 cycloalkyl, or R10 and R11 are taken together with the nitrogen they attached form a heterocyclic ring.
地址 Watertown MA US
您可能感兴趣的专利